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Abstract
Twenty to thirty percent of psoriasis (Pso) patients will develop psoriatic arthritis (PsA). Detection of Pso patients
that are (at risk for) developing PsA is essential to prevent structural damage. We conducted a systematic search of
five bibliographic databases, up to May 2020. We searched for studies assessing markers (clinical, laboratory,
genetic) associated with the development or presence of PsA in Pso patients. Study selection and quality
assessment of the included studies was performed, followed by a qualitative best evidence synthesis to determine
the level of evidence for a marker and its association with concomitant/developing PsA in Pso. Overall, 259 possible
markers were identified in 119 studies that met the inclusion criteria. Laboratory markers related to inflammation
and bone metabolism reached a strong level of evidence for the association (not prediction) of PsA in Pso. Only
CXCL10 showed strong evidence for a positive predictive value for PsA in Pso. The importance of timely detecting
PsA in a Pso population, and finding more (bio)markers contributing to early detection, remains high.
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Introduction
Psoriatic arthritis (PsA) is an immune-mediated inflam-
matory disease affecting joints and entheses and is
strongly associated with psoriasis (Pso). Twenty to thirty
percent of Pso patients will develop PsA, with an average
lag time between Pso and PsA of 10 years [1, 2]. This lag
time creates a unique opportunity to identify patients
with an increased risk for (developing) PsA. The (timely)
recognition of concomitant PsA, or ideally early
prediction, is important, because untreated PsA can lead
to irreversible joint damage [3, 4]. Treatment of arthritis
leads to an improvement of both function and quality of
life [5]. However, patients with Pso are mostly seen by
physicians (e.g., dermatologists) who are not trained in
recognizing early signs of arthritis. Identifying markers
for PsA in patients with Pso can optimize screening to
detect the onset of PsA as early as possible.
Current screening strategies mostly use questionnaires
based on clinical characteristics to detect PsA [6, 7].
Both characteristics of Pso as well as environmental fac-
tors may be relevant variables for PsA screening [8–10].
Next to clinical characteristics, extensive research has
been done on genetic markers, in both HLA (human
leukocyte antigen) and non-HLA regions [10–12]. Like-
wise, there are laboratory markers involved in
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inflammation pathways who might be able to help detect
PsA in Pso patients [13, 14]. However, most research fo-
cuses on the differentiation between Pso and/or PsA on
one side and healthy controls on the other side. To our
knowledge, no comprehensive overview has been made
to summarize the evidence for these clinical, genetic and
laboratory markers.
Therefore, we conducted a systematic review to iden-
tify possible markers for the onset of PsA in a Pso popu-
lation, with the purpose of providing a comprehensive
summary of the available markers for PsA in Pso.
Material and methods
Protocol
The protocol was designed according to the Preferred
Reporting Items for Systematic review and Meta-Analysis
[15] and registered in Prospero (CRD42018093982).
Search strategy
Five bibliographic databases (PubMed, EMBASE, Web of
Science, Medline and Cochrane) were searched for stud-
ies from January 1, 1990, up to April 29, 2020. Search
terms compromised keywords involving study popula-
tion, study design, and etiology (supplementary table 1).
In addition, reference lists of included articles were used
for cross-reference checking.
Study selection
Studies were screened for eligibility based on title and
abstract by two independent reviewers (MM, JV for la-
boratory and genetic studies; MM and TH for clinical
studies). Potentially relevant papers were assessed in full
text (MM, TH). Any disagreement was resolved by con-
sensus or by discussion with a third reviewer (JR, MW,
JV). Studies were excluded based on the following cri-
teria: (1) < 10 patients per group (Pso and PsA, respect-
ively), (2) age of patients < 18 years, (3) no statistical
comparison between Pso and PsA, and (4) languages
other than English, German, or Dutch. We primarily fo-
cused on studies with a longitudinal design, meaning
that the marker was present before the presentation of
PsA. A very low number of longitudinal studies was
available for laboratory studies (n = 2), and none for
genetic studies. To not miss potential relevant markers
in these two categories, we also included genetic and la-
boratory studies with a cross-sectional design (i.e.,
marker was present at the same time as PsA) as a “sec-
ond best” option. While these might not be useful to
identify predictors for development of PsA, they could
provide information about possible markers for con-
comitant PsA.
Data extraction
Data extracted included study design, patient character-
istics, markers, and outcome. Extraction was performed
by two reviewers, with 10% overlap to check extraction
quality (MM, TH).
Assessment of risk bias
Risk bias was assessed using the Newcastle Ottawa Scale
for case-control and cohort studies [16]. This tool com-
prises three domains: selection, comparability, and out-
come/exposure. A study was considered of “good” quality
when it had a minimum of 3 stars in the selection domain,
1 star in the comparability domain, and 2 stars in the out-
come/exposure domain. “Fair” quality was given when a
study had a minimum of 2 stars in the selection, 1 star in
the compatibility, and 2 stars in the outcome/exposure do-
main [17]. If a study failed to meet these standards, it was
considered to be of “poor” quality. Risk of bias assessment
was performed by two reviewers (MM, TH) independ-
ently. Any disagreement was resolved by consensus or by
discussion with a third reviewer (JR, MW, JV).
Best evidence synthesis
For the best evidence synthesis (BES), we included
markers that either showed a significant difference be-
tween Pso and PsA in at least one study or markers that
showed no significant results in at least two studies (i.e.,
we excluded markers who were only investigated once
and showed no association). Markers were grouped into
overarching categories (see Tables 1, 2 and 3). In addition,
for markers presented as a categorical variable, we used
the data of the most extreme level. For example, in the
study from Love et al., body mass index (BMI) was catego-
rized into four levels: < 25 (normal), 25–30, 30–35, > 35
kg/m2 [33]. For the best evidence synthesis, we looked at
the highest level (i.e., BMI > 35 kg/m2) compared to refer-
ence level (i.e., BMI < 25 kg/m2). We then assessed the
consistency of the results within and across studies. If
within a study, a marker was represented in multiple non-
hierarchical conceptually similar constructs, we consid-
ered the result consistent if ≥ 75% of the constructs
pointed in the same direction. Otherwise, we considered
the result for that marker “mixed.” For example, one study
looked at fracture, any trauma, and trauma leading to
medical care [21]. Because two of these were not predict-
ive of PsA, and one was, we considered this study to have
“mixed results” with respect to the marker “trauma.”
If across multiple studies, < 75% of studies were in
agreement with each other, we considered this “conflicting
evidence.” If ≥ 75% of studies were in agreement, we ap-
plied the evidence grading according to Sackett [17]. Be-
cause only a small minority of the included studies were
of “good” quality, we adapted the Sackett best evidence
synthesis as follows: strong evidence in case of two or
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Table 1 Best evidence synthesis of clinical markers
Category Marker Good/fair quality studies Poor quality studies Evidence
Comorbidities Diabetes mellitus 2x no association [18, 19] Strong evidence of no
association




1x positive association [20]
1x no association [18]
Conflicting evidence




(worsening) Fatigue 1x positive association [22] Moderate evidence of
positive association
Worsening function 1x positive association [22] Moderate evidence of
positive association
Younger age at Pso onset 2x positive association [23, 24]




Arthralgia in women (not
men)
1x positive association [22] Moderate evidence of
positive association
Cortical vBMD entheseal 1x negative association [26] Moderate evidence of
negative association
Heel pain 1x positive association [22] Moderate evidence of
positive association
(worsening) Stiffness 1x positive association [22] Moderate evidence of
positive association
Structural entheseal lesion 1x positive association [26] Moderate evidence of
positive association




Duration of Pso 1x no association [27] 1x positive association [28] Conflicting evidence
Intergluteal lesions 1x positive association [25] Moderate evidence of
positive association
Nail pitting 1x positive association [18] Moderate evidence of
positive association
Psoriatic nail lesion 3x no association [18, 19, 27]
1x positive association [25]
Strong evidence of no
association
Scalp lesions 1x no association [27]
1x positive association [25]
Conflicting evidence
Severity of Pso 2x no association [20, 27]
3x positive association [18, 22,
25]
1x positive association [28] Conflicting evidence




1x no association [20] 1x no association [21] Moderate evidence of
no association
Menopause 3x no association [18–20] Strong evidence of no
association
Oral contraceptives 2x no association [19, 20] 1x no association [21] Strong evidence of no
association
Pregnancy 1x no association [20]
1x negative association [19]
1x no association [21] Conflicting evidence
Intoxication Alcohol consumption 3x no association [18–20]
1x mixed results [29]
3x no association [21, 28,
30]
Strong evidence of no
association
Current smoking 2x negative association [20, 31]
2x no association [18, 29]
1x negative association [28]
1x no association [32]
Conflicting evidence
Past smoking 3x no association [18, 29, 31]
1x negative association [20]
2x no association [28, 32] Strong evidence of no
association
Smoking intensity 1x positive association [32] Limited evidence of
positive association
Medication Corticosteroids use 1x positive association [19] Moderate evidence of
positive association
Influenza vaccination 1x no association [20] 1x no association [21] Moderate evidence of
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more studies with good or fair quality, moderate evidence
in case of two or more studies with low quality or one
study of good or fair quality, and limited evidence in case
of one study with low quality. In case of two or more
good/fair quality studies, the results of the poor quality
studies were not taken into account for the BES. The het-




The search yielded 5517 non-duplicate articles and, in
addition, 14 studies were included via cross-reference
checking. After screening on title and abstract, 221 arti-
cles were assessed in full text. A total of 119 studies met
the selection criteria and were included. Of these, 19
studied clinical markers [18–36], 69 studied laboratory
markers [27, 37, 38, 40–55, 57–73, 75–96, 124–133],
and 32 studied genetic markers [97–113, 115–123, 134–
139]. One study described both clinical and laboratory
markers [27]. A flow chart of the selection process is
shown in Fig. 1.
Study characteristics
The characteristics of the included studies are listed in
supplementary table 2. All clinical studies had a
Table 1 Best evidence synthesis of clinical markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
no association
Methotrexate use 2x no association [18, 19] Strong evidence of no
association
Retinoid use 1x positive association [18] Moderate evidence of
positive association
Rubella vaccination 1x no association [20] 1x positive association [21] Conflicting evidence
Tetanus vaccination 1x no association [20] 1x no association [21] Moderate evidence of
no association
Patient characteristics Age 4x no association [20, 22, 25,
27]
Strong evidence of no
association
BMI 3x no association [18, 22, 27]
2x positive association [29, 33]
1x positive association [34] Conflicting evidence
BMI at 18 years 1x positive association [24] 1x no association [34] Conflicting evidence
Patient reported family
history of PsA
3x no association [18, 20, 27] Strong evidence of no
association
Female sex 3x no association [20, 22, 27] 1x no association [28] Strong evidence of no
association
Hip circumference 1x positive association [34] Limited evidence of
positive association
University or high school
level of education
1x no association [20]
1x negative association [18]
Conflicting evidence
Waist circumference 1x positive association [34] Limited evidence of
positive association
Waist-hip ratio 1x positive association [34] Limited evidence of
positive association
Weight increase from 18
years
1x positive association [34] Limited evidence of
positive association
Physical stress Lifting heavy loads 1x positive association [20] Moderate evidence of
positive association
Trauma 2x no association [19, 20] 1x mixed results [21]
1x positive association [35]
Strong evidence of no
association
Psychological distress Anxiety/depression 2x no association [18, 20]
1x positive association [36]
1x no association [21] Conflicting evidence
Change in work status 1x no association [20] 1x no association [21] Moderate evidence of
no association
Death of a family member 1x no association [20] 1x no association [21] Moderate evidence of
no association
Move to a new house 1x no association [20] 1x positive association [21] Conflicting evidence
Psychological distress 1x no association [22]
1x no association [19]
Strong evidence of no
association
A positive association is defined as a higher risk of PsA when the marker is present/increased/higher. A negative association is defined as a lower risk of PsA when
the marker is present/increased/higher
BMI body mass index, PsA psoriatic arthritis, Pso psoriasis, vBMD volumetric bone mineral density
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Table 2 Best evidence synthesis of laboratory markers
Category Marker Good/fair quality studies Poor quality studies Evidence
ACPA Anti-CCP 3x positive association [37–39]
1x not associated [40]
Moderate evidence of
positive association
Anti-MCV 1x positive association [41] Limited evidence of positive
association
Bone metabolism 25(OH) vitamin D 2x no association [42, 43] 3x no association [44–46] Strong evidence of no
association
Alkalic phosphate 1x no association [43] 2x no association [47, 48] Moderate evidence of no
association
Calcium 2x no association [47, 48] Moderate evidence of no
association
COMP 1x no association [49] 1x no association [50] Moderate evidence of no
association
CPII:C2C 1x positive association [49] Moderate evidence of
positive association
CTX 2x no association [47, 51] Moderate evidence of no
association
DKK-1 1x no association [52] 1x positive association [53] Conflicting evidence
MMP3 3x positive association [49,
52, 54]
1x no association [51] Strong evidence of positive
association
OPG 2x positive association [49,
52]
4x no association [50, 51, 53,
55]
Strong evidence of positive
association
OPG/RANKL ratio 2x negative association [50, 56] Moderate evidence of
negative association
Osteoclast precursors 1x positive association [56] Limited evidence of positive
association
Phosphate 1x no association [43] 1x no association [47] Moderate evidence of no
association
RANKL 1x no association [49] 2x positive association [56, 57]
3x no association [50, 51, 53]
Conflicting evidence
Urine Hp 1x negative association [48] Limited evidence of negative
association
Cell culture IL-2 secretion 1x positive association [58] Limited evidence of positive
association
IL-17 secretion 1x positive association [59]
1x no association [58]
Conflicting evidence
Cytokines (Change in) CXCL10 1x positive association [27]
1x positive association [60]
Strong evidence of positive
association
IL-6 1x positive association [61]
1x positive association [62]
1x positive association [63]
1x no association [64]
Strong evidence of positive
association
IL-12/23 p40 1x no association [49] 1x positive association [56] Conflicting evidence
IL-23 1x positive association [65] Limited evidence of positive
association
IL-33 1x positive association [56] Limited evidence of positive
association
IL-34 1x positive association [66] 1x positive association [56] Moderate evidence of
positive association
IL-35 1x positive association [56] Limited evidence of positive
association
IL-36a 1x negative association [56] Limited evidence of negative
association
IL-38 1x positive association [56] Limited evidence of positive
association
M-CSF 1x negative association [52] 1x positive association [53] Conflicting evidence
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Table 2 Best evidence synthesis of laboratory markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
TNFα 2x positive association [56, 64] Moderate evidence of
positive association








1x negative association [67] Limited evidence of negative
association
CD4 + CD45RA-IFNy+ 1x negative association [67] Limited evidence of negative
association
CD4 + CD45RA-IL17+ 1x positive association [67] Limited evidence of positive
association
CD4 + TEMCXCR3 +
CCR4-
1x negative association [67] Limited evidence of negative
association




1x positive association [67] Limited evidence of positive
association
CD8 + CD45RA-IL17+ 1x positive association [67] Limited evidence of positive
association
CD8 + TCMCD69+ 1x positive association [67] Limited evidence of positive
association
CD8 + TEMIL17A+ 1x positive association [67] Limited evidence of positive
association
CD8 + TEMRACCR6 +
CXCR3-CD69-
1x positive association [67] Limited evidence of positive
association
CD8 + TEMRACXCR3 +
CCR4-
1x negative association [67] Limited evidence of negative
association
CD8 + TEMRACXCR3 +
CCR6-CD69+




2x positive association [68, 69] Moderate evidence of
positive association
Monocyte count 1x positive association [70] Limited evidence of positive
association




1x positive association [70] Limited evidence of positive
association





1x positive association [70] Limited evidence of positive
association
White blood count 1x positive association [70]
1x no association [46]
Conflicting evidence
Inflammation marker CRP 5x positive association [43,
49, 54, 66, 71]
1x no association [27]
8x positive association [44, 47,
53, 56, 70, 72–74]
4x no association [46, 58, 64,
75]
Strong evidence of positive
association
ESR 1x positive association [66]
1x no association [43]
5x positive association [44, 47,
56, 70, 74]
2x no association [62, 75]
Conflicting evidence
Lipid metabolism Adiponectin 1x positive association [71] 1x negative association [64] Conflicting evidence
ApoA to ApoB ratio 1x positive association [76] Limited evidence of positive
association
Mulder et al. Arthritis Research & Therapy          (2021) 23:168 Page 6 of 22
Table 2 Best evidence synthesis of laboratory markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
ApoB 1x positive association [76] Limited evidence of positive
association
CER 1x positive association [46] Limited evidence of positive
association
Glucose 2x no association [42, 71] 4x no association [46, 62, 76,
77]
Strong evidence of no
association
HDL 2x no association [42, 71] 3x no association [62, 72, 77] Strong evidence of no
association
Insulin 1x negative association [77] Limited evidence of negative
association
LDL 2x no association [42, 71] 3x no associated [46, 72, 76]
1x positive association [62]
Strong evidence of no
association
LDL:HDL ratio 2x positive association [62, 76] Moderate evidence of
positive association
Leptin 1x positive association [71] 1x no association [64] Conflicting evidence
Total cholesterol 1x negative association [42]
1x no association [71]
2x no association [76, 77]
1x positive association [62]
Conflicting evidence
Total cholesterol/HDL 1x no association [42] 1x positive association [76] Conflicting evidence
Triglycerides 2x no association [42, 71] 4x no association [42, 46, 76,
77]
2x positive association [62, 72]
Strong evidence of no
association
VLDL 2x no association [62, 76] Moderate evidence of no
association
miRNA expression let-7b-3p 1x negative association [78] Moderate evidence of
negative association
let-7b-5p 1x negative association [78] Moderate evidence of
negative association
let-7e-5p 1x positive association [78] Moderate evidence of
positive association
miR-26a-5p 1x positive association [78] Moderate evidence of
positive association
miR-27a-3p 1x positive association [78] Moderate evidence of
positive association
miR-27b-3p 1x positive association [78] Moderate evidence of
positive association
miR-29a-3p 1x positive association [78] Moderate evidence of
positive association
miR-30e-5p 1x positive association [78] Moderate evidence of
positive association
miR-92a-3p 1x negative association [78] Moderate evidence of
negative association
miR-92b-3p 1x negative association [78] Moderate evidence of
negative association
miR-98-5p 1x positive association [78] Moderate evidence of
positive association
miR-139-3p 1x negative association [78] Moderate evidence of
negative association
miR-146a-5p 1x positive association [78] 1x positive association [79] Moderate evidence of
positive association
miR-203a 1x negative association [78] Moderate evidence of
negative association
miR-486-5p 1x negative association [78] Moderate evidence of
negative association
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Table 2 Best evidence synthesis of laboratory markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
miR-1180-3p 1x negative association [78] Moderate evidence of
negative association
miR-2379-5p 1x positive association [78] Moderate evidence of
positive association
miR-3158-3p 1x negative association [78] Moderate evidence of
negative association




CCL1 1x negative association [80] Moderate evidence of
negative association
CCL7 1x negative association [80] Moderate evidence of
negative association
CCL20 1x negative association [80] Moderate evidence of
negative association
CX3CL1 1x negative association [80] Moderate evidence of
negative association
CXCL2 1x negative association [80] Moderate evidence of
negative association
CXCL5 1x negative association [80] Moderate evidence of
negative association
HAT1 1x positive association [81] Limited evidence of positive
association
IL-3 1x negative association [80] Moderate evidence of
negative association
IL-6 1x negative association [80] Moderate evidence of
negative association
IL-8 1x negative association [80] Moderate evidence of
negative association
IL-17C 1x negative association [80] Moderate evidence of
negative association
IL-17F 1x negative association [80] Moderate evidence of
negative association
ISG20 1x negative association [80] Moderate evidence of
negative association
MMP-3 1x negative association [80] Moderate evidence of
negative association
NOTCH2NL 1x negative association [81] Limited evidence of negative
association
SET2D 1x negative association [81] Limited evidence of negative
association
STAT3 1x negative association [80] Moderate evidence of
negative association
STAT6 1x negative association [80] Moderate evidence of
negative association
SYK 1x negative association [80] Moderate evidence of
negative association
TBX21 1x negative association [80] Moderate evidence of
negative association
Serum CD5L 1x positive association [54] Moderate evidence of
positive association
Creatinine 1x no association [43] 1x no association [53] Moderate evidence of no
association
Complement C9 1x negative association [82] Limited evidence of negative
association
Mulder et al. Arthritis Research & Therapy          (2021) 23:168 Page 8 of 22
Table 2 Best evidence synthesis of laboratory markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
IFI16 1x negative association [83] Moderate evidence of
negative association
sIL2R 1x positive association [61] Moderate evidence of
positive association
ITGB5 1x positive association [54] Moderate evidence of
positive association
Gelsolin 1x negative association [44] Limited association of
negative association
K17 1x positive association [84] Limited evidence of positive
association
M2BP 1x positive association [54] Moderate evidence of
positive association
MPO 1x positive association [54] Moderate evidence of
positive association
PRL 1x positive association [85] Limited evidence of positive
association
STIP1 1x positive association [84] Limited evidence of positive
association
Uric acid 1x positive association [86]
1x no association [87]
1x no association [88]
1x negative association [77]
Conflicting evidence
VCP 1x positive association [89] Limited evidence of positive
association
VEGFR-3 1x positive association [90] Limited evidence of positive
association
YKL-40 1x positive association [91] Limited evidence of positive
association
Skin C16ORF61 1x positive association [92] Limited evidence of positive
association
CPN2 1x positive association [92] Limited evidence of positive
association
CXCL12 1x positive association [93] Limited evidence of positive
association
FHL1 1x positive association [92] Limited evidence of positive
association
GPS1 1x positive association [92] Limited evidence of positive
association
IL23R 1x positive association [94] Limited evidence of positive
association
ITGB5 1x positive association [92] Limited evidence of positive
association
POSTN 1x positive association [92] Limited evidence of positive
association
PP2R4 1x positive association [92] Limited evidence of positive
association
SNCA 1x positive association [92] Limited evidence of positive
association
SRP14 1x positive association [92] Limited evidence of positive
association




1x positive association [95] Limited evidence of positive
association
Anti-LL37 antibodies 1x positive association [95]
1x mixed results [82]
Conflicting evidence
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longitudinal design. Two laboratory studies had a longi-
tudinal design and 67 had a cross-sectional design. All of
the genetic studies had a cross-sectional design. Based
on the criteria described in the best evidence synthesis,
259 markers were selected for further description (clin-
ical 51, laboratory 137, genetic 71), of which 104 were
described in multiple studies (clinical 32, laboratory 36,
genetic 36). All markers are shown in supplementary
tables 3, 4, 5.
Quality assessment
Of the included studies, 19 studies were qualified as
good quality, 11 studies were qualified as fair quality,
and 89 studies were qualified as poor quality. Quality as-
sessment of the included studies is shown in supplemen-
tary tables 6 and 7.
Best evidence synthesis
Qualitative best evidence synthesis is depicted separately
for clinical, laboratory, and genetic studies in Tables 1, 2
and 3. With respect to predictive markers for PsA in
Pso, we report the markers for which there was at least a
moderate level of evidence, or which were investigated
in more than one study. With respect to markers associ-
ated with the presence of PsA in Pso, we report only the
markers which were investigated in more than one
study. An overview of the most promising findings is
also shown in Fig. 2.
Clinical markers
Strong level of evidence
Strong evidence was available for 13 of the 51 investi-
gated clinical markers. All these markers showed no
association with the development of PsA in Pso patients.
These markers included the following: diabetes [18, 19],
diarrhea [18, 20], psoriatic nail lesion [18, 19, 25, 27],
menopause [18–20], oral contraceptives [19, 20], alcohol
consumption [18–21, 28–30], past smoking [18, 20, 28,
29, 31, 32], methotrexate use [18, 19], age [20, 22, 27,
29], a patient reported family history of PsA [18, 20, 27],
female sex [20, 22, 27, 28], trauma [19–21, 35], and psy-
chological distress [22, 23]. There was no strong evi-
dence available for clinical markers that had a positive
or negative (i.e., protective) association with the develop-
ment of PsA.
Moderate level of evidence
Moderate evidence was available for 20 of 51 clinical
markers. Only six of them were investigated in more than
one study. All of these markers showed no association
with the development of PsA in Pso. These markers in-
cluded the following: fertility treatment [20, 21], hormone
replacement therapy [20, 21], influenza vaccination [20,
21], tetanus vaccination [20, 21], change in work status
[20, 21], and death of a family member [20, 21].
Moderate evidence of a positive association was avail-
able for 13 clinical markers. These included the follow-
ing: uveitis [18], (worsening) fatigue [22], (worsening)
function [22], (worsening) pain [22], (worsening) stiff-
ness [22], arthralgia in women [22], heel pain [22], struc-
tural entheseal lesions [26], intergluteal skin lesion [25],
nail pitting [18], corticosteroid use [19], retinoid use
[18], and lifting heavy loads [20].
Moderate evidence of a negative association was avail-
able for 1 marker: entheseal cortical volumetric bone
mineral density (vBMD) [26].
Table 2 Best evidence synthesis of laboratory markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
Arylesterase activity 1x positive association [72] Limited evidence of positive
association
Hemoglobin 1x negative association [70] Limited evidence of negative
association
IgG response to C
region of rM12
protein
1x positive association [96] Limited evidence of positive
association
A positive association is defined as a higher risk of PsA when the marker is present/increased/higher. A negative association is defined as a lower risk of PsA when
the marker is present/increased/higher
ACPA anti citrullinated protein antibodies, ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs; anti-CCP, anti-cyclic citrullinated protein; Apo
apolipoprotein, C16ORF61 endosomal protein sorting factor like (VSP35L), C2C collagen fragment neoepitopes Col2-3/4 (long mono), CCL C-C chemokine ligand,
CCR C-C chemokine receptor, CD, cluster of differentiation, CD5L CD5 ligand, CER ceramide, CM central memory, COMP cartilage oligomeric matrix protein, CPII C-
propeptide of type II collagen, CPN2 carboxypeptidase N subunit 2, CRP C-reactive protein, CTX collagen type I C-telopeptide, CX3CL C-X3-C motif ligand, CXCL C-X-
C motif ligand, CXCR C-X-C motif receptor, DKK Dickkopf, EM effector memory, ESR erythrocyte sedimentation rate, FHL1 four and a half LIM domains, GPS G
protein pathway suppressor, HAT human airway trypsin-like protein, HDL high-density lipoprotein, Hp hydroxyproline, IFI interferon-inducible protein, IFN
interferon, IgG immunoglobulin G, IL interleukin, IL23R IL23 receptor, ISG interferon stimulated gene, ITGB integrin beta, K17, keratin 17, LDL low-density
lipoprotein, M2BP Mac-2-binding protein, M-CSF macrophage colony-stimulating factor, MCV mutated citrullinated vimentin, miRNA micro RNA, MMP matrix
metalloproteinase, MPO myeloperoxidase, mRNA messenger RNA, OPG osteoprotegerin, POSTN periostin, PPP2R4 protein phosphatase 2 phosphatase activator
(PTPA);PRL, prolactin, RANKL receptor activator of nuclear factor kappa-B ligand, RNA ribonucleic acid, SETD SET domain protein, sIL-2R soluble IL-2 receptor, SNCA
synuclein alpha, SRP signal recognition particle, SRPX sushi repeat containing protein X-linked, STAT signal transducer and activator of transcription, STIP stress-
inducible phosphoprotein, SYK spleen-associated tyrosine kinase, TBX T-box, TNF tumor necrosis factor, VCP valosin-containing protein, VEGFR vascular endothelial
growth factor receptor, VLDL very low-density lipoprotein
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Table 3 Best evidence synthesis of genetic markers
Category Marker Good/fair quality studies Poor quality studies Evidence




1x positive association [98] Moderate evidence of positive
association
Haplotype B*18-C*07 1x positive association [99] Limited evidence of positive
association
Haplotype B*27-C*01 2x positive association [97, 99] Moderate evidence of positive
association
Haplotype B*27-C*02 3x positive association [97, 99,
100]








1x negative association [98] Moderate evidence of
negative association
Haplotype B*37-C*06 1x negative association [97] Limited evidence of negative
association
Haplotype B*38-C*12 3x positive association [97, 99,
100]
Moderate evidence of positive
association
Haplotype B*39:01-C*12 2x positive association [97, 100] Moderate evidence of positive
association




1x negative association [99] Limited evidence of negative
association
HLA-A*03 1x mixed results [101] Conflicting evidence
HLA-B*08 2x positive association [97, 99]
3x no association [100, 102, 103]
Conflicting evidence
HLA-B*13 1x mixed results [101]
2x no association [102, 104]
Conflicting evidence
HLA-B*18 1x positive association [97]
1x no association [100]
Conflicting evidence
HLA-B*27 6x positive association [97, 99,
100, 103–105]
1x no association [102]
Moderate evidence of positive
association
HLA-B*37 1x negative association [97]
1x no association [102]
Conflicting evidence
HLA-B*38 3x positive association [97, 99,
100]
1x no association [104]
1x mixed results [101]
Conflicting evidence
HLA-B*39 1x positive association [100]
1x mixed results [97]
Conflicting evidence
HLA-B*40 1x negative association [97] Limited evidence of negative
association
HLA-B*44 1x negative association [97] Limited evidence of negative
association
HLA-B*57 1x negative association [99]
3x no association [100, 102, 104]
Moderate evidence of no
association
HLA-B*70 1x mixed results [101] Conflicting evidence
HLA-B amino acid position
45 Glu
1x positive association [106]
2x no association [102, 103]
Conflicting evidence
HLA-B amino acid position
95 Leu
1x positive association [102] Limited evidence of positive
association
HLA-B amino acid position 1x mixed results [103] Conflicting evidence
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Table 3 Best evidence synthesis of genetic markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
97 Arg 1x no association [102]
HLA-C*01 1x positive association [99]
3x no association [97, 100, 102]
Moderate evidence of no
association
HLA-C*02 2x positive association [97, 99]
2x no association [100, 102]
Conflicting evidence
HLA-C*06 1x negative association
[107]
7x negative association [97, 99,
102–105, 108]
2x no association [100, 109]
1x mixed results [101]
Moderate evidence of
negative association
HLA-C*07 1x positive association [99]
2x no association [100, 102]
Conflicting evidence
HLA-C*08 1x negative association [105] Limited evidence of negative
association
HLA-C*12 1x positive association [100]
2x no association [99]
Conflicting evidence
HLA-C amino acid position
305 Ala
1x positive association [102] Limited evidence of positive
association
HLA-C rs10484554 1x positive association [110] Limited evidence of positive
association
HLA-C rs12191877 1x negative association [111] Limited evidence of negative
association
HLA-DQB1*02 1x mixed results [101]
1x no association [102]
Conflicting evidence
HLA-DRB1*03 2x no association [101, 102] Moderate evidence of no
association
HLA-DR*04 1x positive association [101] Limited evidence of positive
association
HLA-DR*07 1x negative association [105] Limited evidence of negative
association
HLA-DR*11 1x mixed results [101] Conflicting evidence
Non-HLA ADAMTS9-MAG1 deletion 1x positive association [112] Limited evidence of positive
association
CCR2 rs1799864 1x positive association [113] Limited evidence of positive
association
IL1RN rs397211 2x no association [111, 114] Moderate evidence of no
association
IL12B rs2082412 2x negative association [111, 114] Moderate evidence of
negative association
IL12B rs3212227 1x no association [115] 1x no association [109] Moderate evidence of no
association
IL12B rs6887695 1x no association [115] 1x no association [109] Moderate evidence of no
association
IL13 rs1800925 1x positive association [116] 1x positive association [117] Moderate evidence of positive
association
IL13 rs20541 2x positive association [114, 117]
1x not associated [111]
Conflicting evidence
IL13 rs848 1x positive association [116] Moderate evidence of positive
association
IL17E rs79877597 1x positive association [118] Limited evidence of positive
association
IL23A rs2066807 2x not associated [111, 114] Moderate evidence of no
association
IL23R rs11209026 1x no association [115] 1x no association [109] Moderate evidence of no
association
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Conflicting evidence
Conflicting evidence was available for 13 of 51 clinical
markers. These markers included several disease charac-
teristics: younger age at Pso onset [23–25], longer dur-
ation of Pso [27, 28], presence of scalp lesions [25, 27],
more severe Pso [18, 20, 22, 25, 27, 28], and higher BMI
[18, 22, 27, 29, 33, 34]. Conflicting evidence was also
found for infection requiring antibiotics [18, 20], preg-
nancy [19–21], current smoking [18, 20, 28, 29, 31, 32],
rubella vaccination [20, 21], university or high school
level of education [18, 20], anxiety/depression [18, 20,
21, 36], and moving to a new home [20, 21].
Laboratory markers
Strong level of evidence
Strong evidence was available for nine of 137 investi-
gated laboratory markers. CXCL10 (C-X-C motif ligand
10) was the only laboratory marker which showed a
positive association with the development of PsA in Pso
patients. It was also the only laboratory marker studied
in a longitudinal design.
Four markers showed a strong level of evidence for a
positive association with the presence of PsA in Pso: a
higher level of matrix metalloproteinase 3 (MMP3) [49, 51,
52, 54], a higher level of osteoprotegerin (OPG) [49–53,
Table 3 Best evidence synthesis of genetic markers (Continued)
Category Marker Good/fair quality studies Poor quality studies Evidence
IL23R rs2201841 1x negative association [111]
1x not associated [114]
Conflicting evidence
KIR2DS1 pos/C2 neg 1x positive association [119] Limited evidence of positive
association
LOC100505817 rs4891505 1x positive association [120] Limited evidence of positive
association
MICA*00701/026 1x positive association [98] Moderate evidence of positive
association
MICA*00801 1x positive association [98] Moderate evidence of positive
association
MICA*016 1x negative association [98] Moderate evidence of
negative association
NFKBIA rs7152376 1x positive association [107] Moderate evidence of positive
association
PTPN22 rs2476601 1x positive association [121] Limited evidence of positive
association
TNFa-238 2x not associated [109, 122] Moderate evidence of no
association
TNFa-308 2x not associated [109, 122] Moderate evidence of no
association
TNFa-857 1x positive association [109] Limited evidence of positive
association
TNFacd haplotype a6c1d3 1x positive association [123] Limited evidence of positive
association
TNFAIP3 rs610604 2x not associated [111, 114] Moderate evidence of no
association
TNIP rs17728338 2x not associated [111, 114] Moderate evidence of no
association
TRAF3IP2 rs240993 1x not associated [114] Limited evidence of no
association
TRAF3IP2 rs458017 1x not associated [110] Limited evidence of no
association
TSC1 rs1076160 2x not associated [111, 114] Moderate evidence of no
association
ZNF816A 1x negative association [114] Limited evidence of negative
association
A positive association is defined as a higher risk of PsA when the marker is present/increased/higher. A negative association is defined as a lower risk of PsA when
the marker is present/increased/higher.
ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs, Arg arginine, CCR C-C motif receptor, Glu glutamic acid, HLA human leukocyte antigen, IL
interleukin, IL1RN IL-1 receptor antagonist, IL23R IL-23 receptor, KIR killer-cell immunoglobulin-like receptor, MAGImembrane-associated guanylate kinase, MICA MHC
class I polypeptide-related sequence A, PTPN22 protein tyrosine phosphatase non-receptor type 22, TNF tumor necrosis factor, TNFAIP TNF alpha-induced protein, TNIP
TNFAIP3-interacting protein, TRAF TNF receptor-associated factor, TRAF3IP TRAF3-interacting protein, TSC1 tuberous sclerosis 1, ZNF zinc finger protein
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55], a higher level of interleukin 6 (IL-6) [61–64], and a
higher level of C-reactive protein (CRP) [27, 43, 44, 47, 49,
53, 54, 56, 62, 64, 66, 70–75, 124, 130].
Five markers showed a strong level of evidence for no
association with PsA in Pso: vitamin D [42–45, 130],
serum glucose [42, 62, 71, 76, 77, 130], serum triglycer-
ides [42, 46, 62, 71, 72, 76, 77], serum high-density lipo-
protein (HDL) [42, 62, 71, 72, 77], and serum low-
density lipoprotein (LDL) [42, 50, 51, 53, 55, 62, 71, 72,
76, 130].
Moderate level of evidence
Moderate evidence was available for 56 of 137 investi-
gated laboratory markers. Fourteen of these 56 have
been investigated in more than one study.
Fig. 1 PRISMA flowchart of included studies. PRISMA, preferred reporting items for systematic reviews and meta-analysis; PsA, psoriatic arthritis; Pso, psoriasis
Fig. 2 Overview of most promising predictors for the development of psoriatic arthritis in psoriasis patients. Clinical parameters are depicted in
blue, laboratory parameters are depicted in green. The strongest evidence is available for the predictive value of CXCL10, this is depicted in bold.
CXCL = C-X-C motif ligand; Pso = psoriasis; vBMD = volumetric bone mineral density
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Of those 14 markers, six showed a positive association
with the presence of PsA in Pso: the presence of anti-
citrullinated protein antibodies (ACPA) [37–40], a
higher level of IL-34 [56, 66], a higher level of tumor ne-
crosis factor alpha (TNFα) [56, 64], a higher mean plate-
let volume (MPV) [68, 69], a higher LDL:HDL ratio [62,
64, 71, 76], and the presence of microRNA miR-146a-50
[78, 79].
Only one of the 14 markers which were investigated
more than once showed moderate evidence of a negative
association with the presence of PsA in Pso: a lower ra-
tio of OPG to receptor activator of nuclear factor kappa-
B ligand (RANKL) was associated with the presence of
PsA in Pso [50, 56].
There was moderate evidence for no association for
seven laboratory markers: serum alkalic phosphate [43,
47, 48], serum calcium [47, 48], serum cartilage oligo-
meric matrix protein (COMP) [49, 50], serum phosphate
[43, 47], serum collagen type I C-telopeptide (CTx) [47,
51], serum very low-density lipoprotein (VLDL) [62, 76],
and serum creatinine [43, 53].
Conflicting evidence
Conflicting evidence was available for 14 of 137 labora-
tory markers: markers of bone metabolism (Dickkopf
(DKK1) [52, 53]; RANK-L [49–51, 53, 56, 57]), markers
of lipid metabolism (serum leptin [64, 71]; total serum
cholesterol [42, 62, 71, 76, 77]; total cholesterol: HDL ra-
tio [42, 76]; serum triglycerides [42, 71, 72, 76, 77, 130]),
inflammation markers (erythrocyte sedimentation rate
(ESR) [43, 44, 47, 56, 62, 66, 70, 74, 75], cell numbers
(platelet count [68, 70]; white blood cell count [70,
130]), cell phenotype (IL-17 secretion [58, 59]), cytokine
levels (IL-12/23 p40 [49, 56]; macrophage colony-
stimulating factor (M-CSF) [52, 53]), uric acid [77, 86–
88], and antibodies against LL-37 [82, 95].
Genetic markers
Strong level of evidence
There were no genetic markers which reached a strong
level of evidence for a positive, negative, or no associ-
ation with the presence of PsA.
Moderate level of evidence
Moderate evidence was available for 30 of 71 investi-
gated genetic markers. Twenty-two of those 31 have
been investigated in more than one study.
Of these 22 markers, six showed a positive association
with the presence of PsA in Pso: the presence of haplo-
type B*27-C*01 [97, 99], haplotype B*27-C*02 [97, 99,
100], haplotype B*38-C*12 [97, 99, 100], haplotype B*39:
01-C*12 [97, 100], the presence of HLA-B*27 [97, 99,
100, 102–105], and the presence of the single nucleotide
polymorphism (SNP) rs1800925 in the IL13 gene [116,
117].
Moderate evidence of a negative association was avail-
able for three markers: the presence of haplotype B*57-
C*06 [97, 99], the presence of HLA-C*06 [97, 99–105,
107–109], and the presence of the SNP rs2082412 in the
IL12B gene [111, 135].
There was moderate evidence for no association for 13
genetic markers: the presence of HLA-B*57 [99, 100,
102, 104], HLA-C*01 [97, 100, 102], HLA-DRB1*03
[101, 102], the presence of the SNP rs397211 of IL1RN
[111, 135], the presence of the SNP’s rs3212227 [109,
115] and rs6887695 in the IL12B gene [109, 115], the
presence of the SNP rs2066807 in IL23A [111, 135], the
presence of the SNP rs11209026 in IL23R [109, 115], the
presence of the SNP rs610604 in TNFAIP3 (TNF alpha-
induced protein 3) [111, 135], the presence of the SNP
rs17728338 in TNIP (TNFAIP3-interacting protein)
[111, 135], the presence of the SNP rs1076160 in TSC1
(tuberous sclerosis 1) [111, 135], and the presence of
TNFa-238 [109, 122] and TNFa-308 [109, 122].
Conflicting evidence
Conflicting evidence was found for 17 of 71 genetic
markers, of which 14 were investigated in more than
one study. These were the presence of HLA-B*08 [97,
99, 100, 102, 103], HLA-B*13 [101, 102, 104], HLA-B*18
[97, 100], HLA-B*37 [97, 102], HLA-B*38 [97, 99–101,
104], HLA-B*39 [97, 100], HLA-C*02 [97, 99, 100, 102],
HLA-C*07 [99, 100, 102], HLA-C*12 [99, 100], HLA-
DQB1*02 [101, 102], the presence of glutamic acid (Glu)
at HLA-B amino acid position 45 [102, 103, 106], the
presence of arginine (Arg) at HLA-B amino position 97
[102, 103], the presence of SNP rs20541 in the IL13 gene
[111, 117, 135], and the presence of SNP rs2201841 in
the IL23R gene [111, 135].
Discussion
In this review, we summarized the available evidence for
possible markers for the onset or presence of PsA in a
Pso patient population in a systematic way. Thereby, we
provide an update and addition to a recent narrative re-
view regarding this subject by Scher et al. [10]. When
looking at clinical markers, we found only strong evi-
dence for markers which were not associated with the
development of PsA. Regarding laboratory markers,
there was strong evidence for the predictive value of (a
change in) CXCL10 serum titers [27, 60]. There was also
strong evidence for the association with (but not predic-
tion of) PsA of several markers related to bone metabol-
ism [49–55] and inflammation [27, 43, 44, 47, 49, 53, 54,
56, 58, 61–64, 66, 70–75, 130]. With respect to genetic
markers, we found no markers which reached a strong
level of evidence for the association with PsA.
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In line with previous beliefs on possible clinical risk
factors [10, 140], we found moderate evidence for a posi-
tive association of gluteal fold lesions [25] and nail pit-
ting for the onset of PsA [18]. However, for nail
involvement in general (e.g., distal onycholysis, oil drop
phenomenon and crumbling), there was strong evidence
of no association [18, 19, 25, 27]. Therefore, this rela-
tionship seemed to be restricted to this specific nail
feature.
Notably, we found conflicting evidence for the predict-
ive value of obesity [18, 20, 22, 27, 29, 33, 34] and psor-
iasis severity [18, 20, 22, 25, 27, 28] for the development
of PsA in Pso patients. These studies may also be prone
to bias because patients with severe Pso differ from pa-
tients with mild Pso in several aspects. For instance,
when looking at Pso severity in particular, one can argue
that more severe skin involvement is treated more inten-
sively, thereby possibly suppressing concomitant arth-
ritis. These kinds of bias may be the reason why these
frequently reported markers reach conflicting evidence
when all the studies are taking into account in a system-
atic way.
When looking at BMI at one unspecified timepoint, this
marker shows conflicting evidence for a relationship with
the development of PsA. In three out of five high/fair
quality studies, there was no association [18, 22, 27], while
two out of five showed a positive association [29, 33]. Even
when taking into account that the before mentioned three
studies are performed in a partially overlapping cohort,
this marker does not reach the 75% agreement level we
consider necessary for a conclusive result. Therefore, BMI
at any unspecified timepoint may not be specific enough
for prediction of PsA. Interestingly, more specified
markers of weight and body composure (e.g., recent
weight gain, BMI at younger age or abdominal adiposity)
showed a positive association with the development of
PsA in Pso but were only investigated in one study of poor
quality [34]. Increasing the evidence in a more detailed
way may be more valid and relevant.
The association of trauma and psoriatic arthritis was
theorized to be due to a deep Koebner phenomenon
[140]. This phenomenon is comparable to the well-
known Koebner phenomenon in the skin, where trauma
can cause the appearance of new skin lesions. The the-
ory on the deep Koebner phenomenon is based on a
study of Thorarensen et al., who used diagnostic codes
to establish two comparable cohorts (Pso with and with-
out PsA) [35]. However, when forming cohorts in this
way, there is a higher risk of misclassification in either
cohort. This study is in disagreement with two other pa-
pers with higher diagnostic certainty [19, 20]. Therefore,
we concluded that there is currently strong evidence that
physical trauma is not associated with a higher rate of
PsA in Pso patients.
The relationship between smoking and PsA devel-
opment has been described previously as the “smok-
ing paradox” [31]. This entails the fact that smoking
appears to be a risk factor for PsA when looking at
the general population, but this association disappears
when only looking at psoriasis patients. This paradox
may be explained by collider bias: bias resulting from
correcting for a variable which is a common effect of
the exposure and outcome [10]. In our review, we
found conflicting evidence for an effect of (current)
smoking [18, 20, 28, 29, 31, 32]. However, due to this
collider bias, it is hard to determine if smoking leads
to additional risk for the development of PsA in a
Pso population, unrelated to its effect on the develop-
ment of Pso. Studies focusing on a change in smoking
status after the development of Pso may shed a light
on this enigma, as suggested by Nguyen [31].
With regard to laboratory markers, only CXCL10 was
studied longitudinally. This cytokine was described in
two good/fair quality studies; both found an association
between CXCL10 and PsA. Pso patients who developed
PsA had a higher CXCL10 serum level at baseline [27].
It was also shown that during the evolution to arthritis
the serum level of CXCL10 diminished: a larger negative
change was associated with a higher risk of PsA [60].
The reason why CXCL10 levels decreased towards the
development of PsA is still unknown. One hypothesis
could be that the psoriasis patient group with a high
level of CXCL10 is more prone to develop arthritis due
to its chemoattractant properties on CXCR3+ CD4+ and
CD8+ T cells [141]. In the evolution towards clinical
manifest PsA, locally produced CXCL10 might get de-
pleted by these infiltrating and locally expanding inflam-
matory cells, subsequently lowering circulating CXCL10
levels over time. However, since these two studies were
published by the same research group, results may be
based on (partially) overlapping patient groups. There-
fore, the predicting value of CXCL10 should be inter-
preted cautiously.
With regard to cross-sectional studies, and markers
that may indicate the presence of PsA in Pso patients,
we found strong evidence for a positive association with
PsA in Pso for markers of inflammation and bone. CRP
is a well-known, widely used inflammatory marker. We
found strong evidence that the CRP level in PsA patients
was higher than in patients with Pso only [27, 43, 44, 47,
49, 53, 54, 56, 64, 66, 70–75, 124, 130]. We argue that
the co-appearance of joint inflammation is responsible
for this observation. However, we found no articles
which studied the level of CRP before the start of PsA in
Pso. Therefore, it is unknown whether it can be used as
a predictive marker. Also, a clear CRP cutoff value for
the presence of PsA (and therefore, specificity and sensi-
tivity) is lacking.
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Other markers for which strong evidence of a positive
association with the development of PsA in Pso exist
were IL-6, MMP3, and OPG. IL-6 is widely regarded as
a marker for systematic inflammation and an important
contributor to the production of CRP by the liver.
MMP3 and OPG are associated with bone metabolism;
one of the hallmark signs of PsA is new bone formation
[142]. Also, untreated arthritis can lead to irreversible
erosions [4]. Therefore, it is not surprising that MMP
and OPG showed an association with the presence of
PsA in our review. In line with CRP, the predictive value
of these markers is unknown, because longitudinal stud-
ies are not performed yet.
Laboratory markers for cardiovascular disease are
studied extensively in psoriatic disease [42, 46, 62, 64,
71, 72, 76, 77, 130]. From these findings, we can con-
clude with strong evidence that these levels do not differ
between psoriasis patients with and without arthritis.
This is in contrast to a recent review which showed that
the prevalence of cardiovascular comorbidities is higher
in patients with PsA when compared to Pso [143]. This
suggests that there are additional factors (e.g., systemic
inflammation) that play a role in cardiovascular morbid-
ity in PsA.
With respect to genetic markers, we focus here on the
most important HLA-markers for Pso and PsA, and the
IL-12 – IL-23 – IL-17 axis. The most important genetic
marker for psoriasis is HLA-C*06, also known as PSOR1
[144]. This marker is responsible for up to 50% of Pso
heritability in the healthy population. It is associated
with type-I (early onset) psoriasis, as well as a guttate
phenotype [145]. Interestingly, our review shows that,
when looking within the population of Pso patients, pa-
tients with the HLA-C*06 marker were less likely to also
have PsA. Despite multiple studies investigating this
marker, high-quality studies are needed to confirm the
robustness of the negative relationship between HLA-
C*06 and the onset of PsA.
We found a moderate level of evidence for the pres-
ence of concomitant PsA in Pso for HLA-B*27, known
for its high prevalence (90%) in ankylosing spondylitis
(AS) [146]. In other diseases of the spondyloarthritis
spectrum, the presence of HLA-B*27 is still higher than
in the general population, but less than in AS. Our re-
view showed that the presence of HLA-B*27 was higher
in the Pso patients who developed arthritis than in the
Pso patients who did not. This could indicate that HLA-
B*27 may be able to differentiate between Pso patients
who do or do not have PsA, which is also considered a
part of the spondyloarthritis spectrum.
When looking at the IL-17/IL-23 axis from a genetic
viewpoint, there was moderate evidence that there are
no SNPs in the IL23 gene for which the presence differs
significantly between PsA and Pso patients [109, 111,
114, 115, 147]. We found limited evidence that the pres-
ence of rs79877597 in the IL17 gene was more common
in PsA versus Pso patients [118]. With regard to the
common IL-12/IL-23 pathway, there was moderate evi-
dence regarding several SNPs in the IL12 gene [148].
We found that the presence of one SNP in IL12
(rs2082412) was lower in PsA versus Pso patients, while
other SNPs in this gene showed no difference [109, 111,
114, 115]. While the IL-17/IL-23 axis may be important
for the development of psoriatic disease in the general
population, these results may indicate that it is of limited
importance in the development of PsA in Pso.
The strengths of this study include the extensiveness
and systematic way of the search with respect to markers
for PsA in patient cohorts with Pso, subsequentially pro-
viding a comprehensive overview of the available evi-
dence. Also, the intertwining of clinical, laboratory, and
genetic markers in a systematic way is unique. By con-
ducting a best evidence synthesis, taking the study qual-
ity into account, we made a qualitative overview of the
extensive data.
The limitations of this systematic review are mostly
due to the limitations of the included studies. Since
there were (almost) no prospective/longitudinal studies
looking at genetic and laboratory markers, we could only
summarize the level of evidence with regard to the rela-
tionship between laboratory and genetic markers with
the presence of PsA in patients with Pso (i.e., only one
predictive factor could be identified). The level of evi-
dence was limited by a paucity of high or fair quality
studies. Mostly, this was because of a lack of appropriate
definition of patient and control groups, in addition to
not adjusting for possible confounders.
Conclusion
This comprehensive systematic review on clinical, la-
boratory, and genetic markers for PsA in patients with
Pso revealed that a useful set of markers is not estab-
lished yet. There were no clinical or genetic markers
with strong evidence which could predict the develop-
ment of PsA in Pso cohorts. There was strong evidence
that laboratory markers related to bone metabolism and
inflammation were associated with the presence of PsA.
Promising is CXCL10, which reached a strong level of
evidence for predicting development of PsA in a Pso
population [27, 60]. The importance of timely detecting
PsA in a Pso population, and finding more (bio)markers
contributing to early detection, remains high.
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lipoprotein; M-CSF: Macrophage colony-stimulating factor;
MMP3: Metalloproteinase 3; MPV: Mean platelet volume;
OPG: Osteoprotegrin; PsA: Psoriatic arthritis; Pso: Psoriasis; RANKL: Receptor
activator of nuclear factor kappa-B ligand; SNP: Single nucleotide
polymorphism; TNF: Tumor necrosis factor; TNFAIP: TNF alpha-induced pro-
tein; TNIP: TNFAIP3-interacting protein; TSC1: Tuberous sclerosis 1;
vBMD: Volumetric bone mineral density; VLDL: Very low-density lipoprotein
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